Cullinan Therapeutics Statistics
Total Valuation
CGEM has a market cap or net worth of $438.85 million. The enterprise value is $31.20 million.
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025, after market close.
Earnings Date | May 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
CGEM has 58.51 million shares outstanding. The number of shares has increased by 29.41% in one year.
Current Share Class | 58.51M |
Shares Outstanding | 58.51M |
Shares Change (YoY) | +29.41% |
Shares Change (QoQ) | +0.42% |
Owned by Insiders (%) | 4.02% |
Owned by Institutions (%) | 83.65% |
Float | 38.98M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.79 |
P/TBV Ratio | 0.73 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.53, with a Debt / Equity ratio of 0.00.
Current Ratio | 13.53 |
Quick Ratio | 13.23 |
Debt / Equity | 0.00 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -32.10% and return on invested capital (ROIC) is -23.44%.
Return on Equity (ROE) | -32.10% |
Return on Assets (ROA) | -22.26% |
Return on Invested Capital (ROIC) | -23.44% |
Return on Capital Employed (ROCE) | -33.31% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.51M |
Employee Count | 111 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
In the past 12 months, CGEM has paid $117,000 in taxes.
Income Tax | 117,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -57.07% in the last 52 weeks. The beta is -0.11, so CGEM's price volatility has been lower than the market average.
Beta (5Y) | -0.11 |
52-Week Price Change | -57.07% |
50-Day Moving Average | 9.27 |
200-Day Moving Average | 14.24 |
Relative Strength Index (RSI) | 29.59 |
Average Volume (20 Days) | 400,445 |
Short Selling Information
The latest short interest is 8.67 million, so 14.83% of the outstanding shares have been sold short.
Short Interest | 8.67M |
Short Previous Month | 8.66M |
Short % of Shares Out | 14.83% |
Short % of Float | 22.25% |
Short Ratio (days to cover) | 19.85 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -196.92M |
Pretax Income | -156.28M |
Net Income | -167.38M |
EBITDA | -196.61M |
EBIT | -196.92M |
Earnings Per Share (EPS) | -$3.11 |
Full Income Statement Balance Sheet
The company has $398.98 million in cash and $2.15 million in debt, giving a net cash position of $396.83 million or $6.78 per share.
Cash & Cash Equivalents | 398.98M |
Total Debt | 2.15M |
Net Cash | 396.83M |
Net Cash Per Share | $6.78 |
Equity (Book Value) | 590.33M |
Book Value Per Share | 10.09 |
Working Capital | 384.02M |
Full Balance Sheet Cash Flow
Operating Cash Flow | -145.30M |
Capital Expenditures | n/a |
Free Cash Flow | -145.30M |
FCF Per Share | -$2.48 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |